AnGes Company Description

AnGes, Inc. engages in the research and development of gene-based medicines.

It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B.

The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

AnGes, Inc.

Country	Japan
Founded	1999
Industry	Pharmaceutical Preparations
Employees	55
CEO	Ei Yamada

Contact Details

Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan
Website	anges.co.jp

Stock Details

Ticker Symbol	AJW
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	JPY
SIC Code	2834

Key Executives

Name	Position
Ei Yamada	Chief Executive Officer